Insights On Outsourced Drug Development
-
Developing Non-PEG Stabilizer Lipids For Nucleic Acid Lipid Nanoparticles
7/1/2026
Non-PEG stabilizer lipids may offer a new path for LNP design. Combining strong colloidal performance with greater chemical flexibility helps address growing concerns around PEG-related immunogenicity.
-
Alzheimer's Disease Pathway
3/24/2025
Alzheimer’s disease (AD) affects 50 million people globally, causing cognitive decline. Explore the signaling pathways of amyloid beta and tau proteins, linking them to neuronal death and AD symptoms.
-
Lessons In Building Connected Lab Operations Across Development And GMP
9/30/2026
Building connected operations across development and GMP environments removes bottlenecks and ensures data integrity. Explore practical insights to scale and standardize your lab workflows.
-
Functional Characterization Of 3D Assembled Neurospheres
4/4/2025
Neural organoids and 3D spheroids offer advanced platforms for brain research and drug discovery. Discover how creating 3D neurospheres from iPSC-derived neurons and astrocytes aids in compound profiling and toxicity testing.
-
How L-Leucine Shapes Spray-Dried Particles
6/17/2026
Optimizing L-Leucine balances porosity and surface enrichment in spray-dried formulations. Precise adjustments alter particle structure to enhance aerodynamic performance and lung deposition.
-
Best-In-Class Nanodevelopment Capabilities
2/3/2025
A highly specialized team excels in creating unique nanoparticles for both small and large molecule APIs. Leveraging cutting-edge technology, they produce nanoformed materials as small as 10 nanometers.
-
Advancing Cell Therapies With Lipid Nanoparticles
3/24/2025
Cell therapies, using reprogrammed immune cells, offer innovative treatments for diseases. Discover how lipid nanoparticles (LNPs) enhance these therapies by delivering RNA for gene modulation and next-gen treatments.
-
Nitrosamine Testing: How To Ensure Regulatory Compliance, Product Safety
9/16/2025
Explore what nitrosamines are, why testing matters, and how we're able to deliver high-confidence solutions through advanced science and industry-leading expertise.
-
Accelerate FDA Approval With Fast Track Designation
7/3/2025
Learn how Fast Track Designation streamlines the FDA review process and offers faster approval for serious diseases or life-threatening conditions.
-
Assessing Viability And Real-Time Apoptosis/Necrosis
3/17/2025
Malignant gliomas are aggressive brain tumors that resist standard treatments. Discover why researchers focus on real-time cell death dynamics to develop targeted therapies and promising strategies.